ReviewJournal of molecular and cellular cardiology plus2026
Multicellular senescence programs in the aged heart.
Review in Journal of molecular and cellular cardiology plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac aging reflects a convergence of intrinsic molecular damage and maladaptive stress responses that progressively erode myocardial resilience. Accumulating genomic instability, telomere dysfunction, chromatin remodeling, and metabolic dysregulation activate innate immune signaling and cellular senescence across cardiomyocytes, endothelial cells, fibroblasts, and immune cells. At the tissue level, these processes manifest as microvascular rarefaction, fibrosis, hypertrophy, neurovascular uncoupling, and impaired adaptive capacity, creating a substrate that overlaps extensively with cardiomyopathy, heart failure, and atrial fibrillation (AF). Importantly, senescence in the heart is not monolithic. Emerging multi-omics and spatial analyses reveal context-dependent senescence programs, including transient, injury-associated states that support angiogenesis and repair, alongside chronic senescent phenotypes that propagate inflammation and remodeling through the senescence-associated secretory phenotype (SASP). These observations indicate that senescence is not uniformly deleterious but rather comprises functionally heterogeneous responses within the aging myocardium. Non-cell autonomous interactions-spanning cardiomyocyte-fibroblast crosstalk, immune niche signaling, endothelial cell-neuronal axis, and systemic organ-to-heart communication-further amplify or constrain these trajectories. Advances in biomarker discovery, imaging, and circulating epigenetic signatures now enable biological aging of the heart to be quantified beyond chronological aging, although many circulating biomarkers are not cardiac-specific and may also reflect systemic inflammation, fibrosis, frailty, or generalized biological aging. In parallel, preclinical studies demonstrate that senolytic, senomorphic, metabolic, and nutrient-sensing-targeted interventions can partially restore cardiac homeostasis. Together, these insights suggest that cellular senescence may represent a key mechanism and a potentially targetable process in cardiac aging, with important implications for the prevention and treatment of age-related cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.